EN DE

Dr FAUCONNET Sylvie

Fiche personne

coordonnées

19 rue Ambroise Paré
Les Hauts du Chazal
25000 BESANCON

03 63 08 22 29

sylvie.fauconnet@univ-fcomte.fr

Territoire

Franche-Comté

Statut

Chercheur

affiliation

Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Université de Franche-Comté (UFC)

équipes/plateformes

Equipe EA 3181 - Equipe "Carcinogenèse associée aux HPV"

Recherche

Mots clés : Vessie,Col de l'utérus,HPV,FABP,Cadhérine,PPAR

Thématique de recherche :

Mise en évidence de marqueurs pronostiques et/ou diagnostiques dans les cancers du col de l'utérus et de la vessie.

Etude des processus qui conduisent à la formation d'une tumeur maligne dans ces cancers. En particulier comprendre les mécanismes impliqués lors de la carcinogenèse : rôle d'une protéine liant les Acides Gras (A-FABP), rôle de molécules d'adhérence dans la progression tumorale (E et N Cadhérines), rôle de ligands de PPAR (Thiazolidinediones) dans l'induction de l'apoptose. L'objectif à terme est de développer des chimiothérapies ciblées.

Publications

Chronic exposure to glucocorticoids induces suboptimal decision-making in mice.

Cabeza L, Ramadan B, Giustiniani J, Houdayer C, Pellequer Y, Gabriel D, Fauconnet S, Haffen E, Risold PY, Fellmann D, Belin D, Peterschmitt Y

Eur Neuropsychopharmacol. 2021 Jan 30;:

Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure.

Elie-Caille C, Lascombe I, Péchery A, Bittard H, Fauconnet S

Mol. Cell. Biochem.. 2020 Jun 9;:

DNA demethylation agent 5azadC downregulates HPV16 E6 expression in cervical cancer cell lines independently of TBX2 expression.

Perrard J, Morel A, Meznad K, Paget-Bailly P, Dalstein V, Guenat D, Mourareau C, Clavel C, Fauconnet S, Baguet A, Mougin C, Pretet JL

Oncol Lett. 2020 Jan;19(1):1074-1081

Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.

Mathis C, Lascombe I, Monnien F, Bittard H, Kleinclauss F, Bedgedjian I, Fauconnet S, Valmary-Degano S

BMC Cancer. 2018 Dec 10;18(1):1239

Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells.

Plissonnier ML, Fauconnet S, Bittard H, Mougin C, Rommelaere J, Lascombe I

Oncotarget. 2017 Dec 8;8(64):107744-107762

Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells.

Péchery A, Fauconnet S, Bittard H, Lascombe I

Tumour Biol.. 2016 Nov;37(11):14789-14802

The PPARbeta agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism.

Roche E, Lascombe I, Bittard H, Mougin C, Fauconnet S

Cell Signal. 2014 Feb;26(2):433-43

Isoliquiritigenin induces caspase-dependent apoptosis via downregulation of HPV16 E6 expression in cervical cancer Ca Ski cells.

Hirchaud F, Hermetet F, Ablise M, Fauconnet S, Vuitton DA, Pretet JL, Mougin C

Planta Med. 2013 Nov;79(17):1628-35

The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL.

Plissonnier ML, Fauconnet S, Bittard H, Lascombe I

PLoS One. 2011;6(12):e28354

Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells.

Plissonnier ML, Fauconnet S, Bittard H, Lascombe I

Int J Cancer. 2010 Oct 15;127(8):1769-84.

Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer

Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H

Oncol Rep. 2009 Jun;21(6):1495-504.

A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells.

Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, Bittard H, Fauconnet S

Int J Cancer. 2009 Apr 15;124(8):1820-8.

N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.

Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H

Clin Cancer Res. 2006 May 1;12(9):2780-7.

Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.

Clairotte A, Lascombe I, Fauconnet S, Mauny F, Felix S, Algros MP, Bittard H, Kantelip B

Am J Clin Pathol. 2006 Jan;125(1):119-26.

Angiogenesis and bladder cancer: role of vascular endothelial growth factor.

LASCOMBE I, FAUCONNET S, CHABANNES E, BITTARD H

In : Progress in Bladder Cancer Research. Pp. 19-65, vol 6, 2005.

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

Wallerand H, Bakkar AA, de Medina SG, Pairon JC, Yang YC, Vordos D, Bittard H, Fauconnet S, Kouyoumdjian JC, Jaurand MC, Zhang ZF, Radvanyi F, Thiery JP, Chopin DK

Carcinogenesis. 2005 Jan;26(1):177-84

Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells.

Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H

J Biol Chem. 2002 Jun 28;277(26):23534-43

Protein kinase C signalling pathway is involved in the regulation of vascular endothelial growth factor expression in human bladder transitional carcinoma cells.

Chabannes E, Fauconnet S, Bernardini S, Wallerand H, Adessi G, Bittard H

Cell Signal. 2001 Aug;13(8):585-91.